Eylea (aflibercept) Injection

A Comprehensive Program for Patient Information and Reimbursement Support

A Comprehensive Program
for Patient Information and
Reimbursement Support

EYLEA Co-Pay Card Program

For patients with commercial insurance (not funded through a government healthcare program).

Now with Enhanced Terms—How the Program Works

*The program does not cover or provide support for supplies, procedures, or any physician-related service associated with EYLEA. General, non-product-specific co-pay, co-insurance, or insurance deductibles are not covered. This program is not valid where prohibited by law, taxed, or restricted. EYLEA4U® reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Additional program conditions apply.

Program Eligibility


EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with Macular Edema following CRVO. The recommended dose for EYLEA is 2 mg administered by injection in the eye monthly (every 4 weeks).


EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept. As with all medications, EYLEA can cause side effects.

Injection into the eye can result in an infection in the eye and retinal detachment. Inflammation in the eye has been reported with the use of EYLEA.

In some patients, injections with EYLEA may trigger a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.

There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.

The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.

Serious side effects related to the injection procedure are rare but can occur including infection inside the eye, retinal detachment, cataract, increased pressure in the eye, and vitreous detachment.

It is important that you contact your doctor right away if you think you might be experiencing any side effects.

EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

To view the publication, you will be directed to a third-party site that is not owned or controlled by Regeneron Pharmaceuticals, Inc. This link is provided as a resource to the viewer. The use of third-party web sites is at your own risk, and is subject to the terms and conditions of such sites.